Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function

Avik Dutta, PhD, Yue Yang, PhD, Bao Le, Golam Mohi, PhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-143163

Published: 2020

Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-134039

Published: 2020

Journal Articles

Critical Requirement of U2AF1 in the Maintenance and Function of Hematopoietic Stem Cells

Avik Dutta, PhD, Yue Yang, PhD, Bao Le, Golam Mohi, PhD

Blood (2019) 134 (Supplement_1): 1195.

https://doi.org/10.1182/blood-2019-132007

Published: 2019

Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD

Blood (2019) 134 (Supplement_1): 4200.

https://doi.org/10.1182/blood-2019-132038

Published: 2019

Journal Articles

The NF-KB Inhibitor DMAPT in Combination with Ruxolitinib Displays Efficacy in Jak2V617F Knock-in Mouse Model of Myeloproliferative Neoplasms

Yue Yang, BS, Dipmoy Nath, PhD, Avik Dutta, MSc, Peter A Crooks, PhD, Golam Mohi, PhD

Blood (2018) 132 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2018-99-120195

Published: 2018

Journal Articles

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD

Blood (2018) 132 (Supplement 1): 54.

https://doi.org/10.1182/blood-2018-99-119421

Published: 2018

Journal Articles

Deletion of PTPN1 Promotes the Development of Myelofibrosis

Fatoumata Jobe, PhD, Bhumika Patel, MD, Hideki Makishima, MD PhD, Bartlomiej P Przychodzen, MSc, Robert E Hutchison, MD, Kendra K Bence, PhD, Jaroslaw P Maciejewski, MD PhD FACP, Golam Mohi, PhD

Blood (2016) 128 (22): 795.

https://doi.org/10.1182/blood.V128.22.795.795

Published: 2016

Journal Articles

Expression of HMGA2 Cooperates with Jak2V617F in the Development of Myelofibrosis

Avik Dutta, MSc, Robert E Hutchison, MD, Golam Mohi, PhD

Blood (2016) 128 (22): 797.

https://doi.org/10.1182/blood.V128.22.797.797

Published: 2016

Journal Articles

Critical Role of SHP2 in the Initiation and Maintenance of Myeloproliferative Neoplasms Evoked By JAK2V617F

Golam Mohi, PhD, Dongqing Yan, PhD, Fatoumata Jobe, Robert E Hutchison, MD

Blood (2015) 126 (23): 483.

https://doi.org/10.1182/blood.V126.23.483.483

Published: 2015

Journal Articles

Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice

Yue Yang, Hajime Akada, PhD, Dipmoy Nath, Robert E Hutchison, MD, Golam Mohi, PhD

Blood (2014) 124 (21): 159.

https://doi.org/10.1182/blood.V124.21.159.159

Published: 2014

Journal Articles

Stat3 Negatively Regulates Myeloproliferative Neoplasm Induced By Jak2V617F

Dongqing Yan, Ph.D., Golam Mohi, PhD

Blood (2013) 122 (21): 111.

https://doi.org/10.1182/blood.V122.21.111.111

Published: 2013

Journal Articles

Critical Role Of Jak2 In The Maintenance and Function Of Adult Hematopoietic Stem Cells

Hajime Akada, Saeko Akada, Golam Mohi, PhD

Blood (2013) 122 (21): 1180.

https://doi.org/10.1182/blood.V122.21.1180.1180

Published: 2013

Journal Articles

Loss of Wild-Type Jak2 Allele Enhances Myeloid Cell Expansion and Accelerates Myelofibrosis in Jak2V617F Knock-in Mice

Hajime Akada, Saeko Akada, Dongqing Yan, Robert Hutchison, MD, Golam Mohi, PhD

Blood (2012) 120 (21): 809.

https://doi.org/10.1182/blood.V120.21.809.809

Published: 2012

Journal Articles

Erythroid Lineage-Restricted Expression of Jak2V617F Is Sufficient to Induce a Myeloproliferative Disease in Mice,

Hajime Akada, Saeko Hamada, Golam Mohi, PhD

Blood (2011) 118 (21): 3861.

https://doi.org/10.1182/blood.V118.21.3861.3861

Published: 2011

Journal Articles

Critical Role for Stat5 in the Initiation and Maintenance of Polycythemia Vera in a Jak2V617F Knock-In Mouse Model

Dongqing Yan, Golam Mohi, PhD

Blood (2011) 118 (21): 121.

https://doi.org/10.1182/blood.V118.21.121.121

Published: 2011

Journal Articles

Conditional Expression of Heterozygous or Homozygous Jak2V617F From Its Endogenous Promoter Induces a Polycythemia Vera-Like Disease.

Hajime Akada, Dongqing Yan, Haiying Zou, Robert E. Hutchison, M. Golam Mohi, PhD

Blood (2009) 114 (22): 437.

https://doi.org/10.1182/blood.V114.22.437.437

Published: 2009

Journal Articles

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

M. Golam Mohi, PhD, Wayne W. Chan, BA, Shaoguang Li, MD, PhD, Benjamin Neel, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2008) 112 (11): 570.

https://doi.org/10.1182/blood.V112.11.570.570

Published: 2008

Journal Articles

Differential Biological Properties and Signaling Effects of Different JAK2 Alleles

M. Golam Mohi, PhD, Dongqing Yan, Haiying Zou

Blood (2008) 112 (11): 3737.

https://doi.org/10.1182/blood.V112.11.3737.3737

Published: 2008

Journal Articles

Activating Shp2 Mutations Cause Progressive Myeloproliferative Disorder in Mice.

M. Golam Mohi, PhD, Gordon Chan, Ph.D, Toshiyuki Araki, Ph.D., Wentien Yang, Ph.D., Lily Pao, Ph.D., Demetrios Kalaitzidis, Ph.D., Benjamin G. Neel, M.D., Ph.D.

Blood (2006) 108 (11): 3614.

https://doi.org/10.1182/blood.V108.11.3614.3614

Published: 2006

Journal Articles

Structural and Signaling Requirements for Transformation Mediated by Shp2 Mutants.

M. Golam Mohi, PhD, Benjamin G. Neel, MD, PhD

Blood (2005) 106 (11): 3508.

https://doi.org/10.1182/blood.V106.11.3508.3508

Published: 2005

NARROW

The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Critical Requirement of U2AF1 in the Maintenance and Function of Hematopoietic Stem Cells

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

The NF-KB Inhibitor DMAPT in Combination with Ruxolitinib Displays Efficacy in Jak2V617F Knock-in Mouse Model of Myeloproliferative Neoplasms

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Deletion of PTPN1 Promotes the Development of Myelofibrosis

Expression of HMGA2 Cooperates with Jak2V617F in the Development of Myelofibrosis

Critical Role of SHP2 in the Initiation and Maintenance of Myeloproliferative Neoplasms Evoked By JAK2V617F

Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice

Stat3 Negatively Regulates Myeloproliferative Neoplasm Induced By Jak2V617F

Critical Role Of Jak2 In The Maintenance and Function Of Adult Hematopoietic Stem Cells

Loss of Wild-Type Jak2 Allele Enhances Myeloid Cell Expansion and Accelerates Myelofibrosis in Jak2V617F Knock-in Mice

Erythroid Lineage-Restricted Expression of Jak2V617F Is Sufficient to Induce a Myeloproliferative Disease in Mice,

Critical Role for Stat5 in the Initiation and Maintenance of Polycythemia Vera in a Jak2V617F Knock-In Mouse Model

Conditional Expression of Heterozygous or Homozygous Jak2V617F From Its Endogenous Promoter Induces a Polycythemia Vera-Like Disease.

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

Differential Biological Properties and Signaling Effects of Different JAK2 Alleles

Activating Shp2 Mutations Cause Progressive Myeloproliferative Disorder in Mice.

Structural and Signaling Requirements for Transformation Mediated by Shp2 Mutants.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only